Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- PRTG
- Price
- 5.23
- Stock movement up
- +0.07 (1.36%)
- Company name
- Portage Biotech Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 11.92M
- Ent value
- 12.16M
- Price/Sales
- -
- Price/Book
- 17.15
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -19.47%
- 1 year return
- -17.77%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-10-30
DIVIDENDS
PRTG does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 17.15 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 2.28M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 1.76M |
| Net receivables | 570.00K |
| Total current assets | 2.69M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 20.00K |
| Total assets | 2.71M |
| Accounts payable | 49.00K |
| Short/Current long term debt | 28.00K |
| Total current liabilities | 873.00K |
| Total liabilities | 2.01M |
| Shareholder's equity | 695.00K |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 5.20 |
| Daily high | 5.60 |
| Daily low | 5.11 |
| Daily Volume | 127K |
| All-time high | 856.20 |
| 1y analyst estimate | 140.00 |
| Beta | 0.64 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| PRTG | S&P500 | |
| Current price drop from All-time high | -99.39% | - |
| Highest price drop | -99.65% | -19.00% |
| Date of highest drop | 13 Dec 2024 | 8 Apr 2025 |
| Avg drop from high | -99.29% | -2.76% |
| Avg time to new high | - | 5 days |
| Max time to new high | 265 days | 89 days |
COMPANY DETAILS
Marketcap
11.92M
Marketcap category
Small-cap
Description
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors; PORT-6, a highly selective A2A receptor antagonist, which is in phase 1a for the treatment of solid tumors; PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials; and PORT-7, a potent and selective antagonist of the adenosine A2B receptor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Employees
3
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner